Hemogenyx Pharmaceuticals PLC Development Agreement
May 14 2018 - 2:00AM
RNS Non-Regulatory
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
14 May 2018
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Development Agreement
Hemogenyx to work with Global pharmaceutical company on CDX
antibodies development
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology
company developing novel therapies to transform bone marrow, or
blood stem cell, transplantation for the treatment of blood
diseases, announces that it has signed a development agreement with
a leading global pharmaceutical company engaged in the research,
development, manufacture and marketing of pharmaceutical
products.
Under the Development Agreement (the "Agreement"), Hemogenyx
will receive on a cost-free basis technical support, access to
advanced methods of discovering, developing and engineering
antibodies, and certain intellectual property which is expected to
assist the successful preclinical development of the Hemogenyx's
lead candidate bi-specific CDX antibodies. This will complement the
Company's own development work currently being undertaken. The
Agreement stipulates certain confidential provisions, including, at
this stage, the pharmaceutical company's identity.
Hemogenyx believes that the Agreement will increase the
probability of its success in bringing CDX antibodies to clinical
trials and beyond. CDX bi-specific antibodies are being developed
in order to replace traditional methods of conditioning patients
for bone marrow transplants. Additionally, they would allow more
patients to benefit from the curative power of bone marrow
transplants by eliminating the need for pre-transplantation
chemotherapy and radiation, which can compromise a patient's
ability to receive such transplants. Hemogenyx is developing its
lead candidate in readiness for the start of Phase 1 trials.
Under the Agreement, Hemogenyx will grant the global
pharmaceutical company a research license for anything jointly
developed under the Agreement, as well as an option for an
exclusive worldwide license to commercially exploit CDX antibodies
or any variants, which will be jointly developed under the
Agreement. If such option is not exercised by the global
pharmaceutical company, the Company has the option to license the
jointly developed CDX antibodies or any variants.
Dr. Vladislav Sandler, CEO of Hemogenyx, said: "This agreement
provides additional support for our development plans for CDX
antibodies, and complements the work that we are already
undertaking with our own resources. This close collaboration offers
the potential for ongoing value-adding licensing arrangements with
a major global pharmaceutical company with the benefit of their
global reach and large-scale resources."
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer Via Walbrook PR
& Co-Founder
Sir Marc Feldmann, Executive Chairman
Optiva Securities Ltd Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey
Walbrook PR (UK Media & Investor Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com
Relations)
Paul McManus Mob: +44 (0)7980 541 893
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249 or Lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly owned U.S. operating
subsidiary, HemoGenyx LLC, located in its state-of-the-art research
facility in Brooklyn, New York. HemoGenyx is a preclinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapies and treatments for blood
diseases such as leukemia and lymphoma. The company's leading
technologies aim to change the way in which bone
marrow/hematopoietic stem cell (BM/HSC) transplants are performed
and improve their efficacy. HemoGenyx's two distinct and
complementary products include an immunotherapy product for patient
conditioning-the CDX bi-specific antibody-and a cell therapy
product for BM/HSC transplantation-the HuPHEC. Each of these
products holds the potential to revolutionize the way BM/HSC
transplants are being performed, offering solutions that mitigate
the dangers and limitations associated with the current standard of
care. For more information, visit www.hemogenyx.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUORRRWUAVAUR
(END) Dow Jones Newswires
May 14, 2018 02:00 ET (06:00 GMT)
Silver Falcon (LSE:SILF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Silver Falcon (LSE:SILF)
Historical Stock Chart
From Aug 2023 to Aug 2024